A four-year-old girl in Shanghai received a custom gene-editing therapy for a rare genetic condition at a cost of $860,000 and died days after the injection; a year later her team published preclinical results in Nature without mentioning the death.

Mei, a four-year-old in Shanghai, received a custom gene-editing therapy for a rare genetic mutation; her family paid $860,000. After viral particles were injected into her spinal cord, she developed a fever and kidney failure and died within days.
A year later the team published its preclinical findings in Nature, Chinese media called it a 'world-class breakthrough,' and neither the death nor the money was mentioned. An investigation in Science this July found the consent form did not warn of possible death, and the hospital approved the treatment before toxicology results showed liver and kidney damage in monkeys.
The author asks not about a villain but about why the system keeps letting this happen.
What stings most, I think, is that a family's desperate hope was treated as a market.


Curated from high-quality sources, with concise summaries and key takeaways.